Companies › ProQR Therapeutics
2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Ophthalmology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sepofarsen (QR-110) CEP290 mRNA positive modulator | CEP290 | Phase 2 | Leber Congenital Amaurosis 10 | – |
| QR-1123 RNA therapeutic targeting P23H mutation in RHO gene (antisense oligonucleotide or similar | RHO | Phase 1 | Autosomal Dominant Retinitis Pigmentosa | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03913143 | Sepofarsen (QR-110) | Phase 2 | Leber Congenital Amaurosis 10 | Ophthalmology | Jan 2022 |
| NCT04123626 | QR-1123 | Phase 1 | Autosomal Dominant Retinitis Pigmentosa | Ophthalmology | Jun 2022 |
Cash of 92m EUR on 2025-12-31; operating cash outflow about 53m EUR a year; runway about 21 months at that burn, to Sep 2027
Ocugen Opus Genetics Laboratoires Thea Kiora Pharmaceuticals GenSight Biologics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.